|
Rigel raises $130M for PhII trial of asthma drug
FierceBiotech Pfizer's decision to cut all allergy and respiratory drug development work came as good news for Rigel Pharmaceuticals, even though it meant the end of the two developers' pact for allergic asthma drug candidate R343. Pfizer bought into Rigel's … |
View full post on asthma – Google News